André Mansinho, Director – Clinical Research at The START Center for Cancer Care, shared a post on LinkedIn:
“Our new review article, ‘Integrating antibody–drug conjugates into solid tumor oncology: Current standards and future directions,’ is now published open-access in the journal Cancer.
Antibody-drug conjugates ADCs are rapidly shifting precision oncology paradigms, moving from historical salvage protocols toward frontline treatment options. This comprehensive review evaluates the structural principles, pharmacology, and clinical implementation strategies necessary to optimize these agents across solid tumors.
Key areas analyzed in the paper:
- Pharmacokinetic and pharmacodynamic complexity: The impact of drug-to-antibody ratio homogeneity, linker chemistry, nonspecific uptake, and FcRn-mediated recycling on defining the therapeutic window.
- Clinical status across solid tumors: Current standards of care and pivotal trial data in breast, gynecologic, gastrointestinal, and lung cancers.
- Next-generation targets and engineering: Clinical potential of emerging targets alongside bispecific and dual-payload constructs.
- Overcoming resistance: Mechanisms of antigen loss, internalization failure, and payload adaptations, paired with rational combination strategies (immunotherapy and targeted agents).”
Title: Integrating antibody-drug conjugates into solid tumor oncology: Current standards and future directions
Authors: André Mansinho, Joana Albuquerque, Andreia Lopes, Emiliano Calvo
Read the Full Article.
